STAR 3 trial results confirm Medtronic's sensor-augmented insulin pump therapy achieves better glucose control than daily insulin injections in people with diabetes.(Clinical report)

In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in Type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today. The data also showed a statistically significant reduction in glycated haemoglobin (A1c) levels, which was sustained over a prolonged one-year period for patients enrolled in the sensor-augmented insulin pump therapy arm of the trial. Study results were simultaneously published online in The New England Journal of Medicine (NEJM) …